The purpose of this study is to look at the differences in how individuals with heart failure
with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and
exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies
function using drugs Sacubatril/Valsartan (Entresto) and MANP.